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Abstract
Background: Several researchers have claimed that classification of tumours on the basis of HER-
2/neu overexpression or amplification may define a subset of breast cancer in which the net effect
of a risk factor could be rather more obvious and its impact on breast cancer development more
clear. We decided to investigate, in a group of patients from a geographical area with a low
incidence of breast cancer, whether HER-2/neu positive tumours are correlated with established
or suspected risk factors for breast cancer and thus to identify distinct subgroups of high risk
women.
Methods: This study analysed data from patients who attended the Breast Unit at the University
Hospital of Heraklion, Crete, Greece between 1996 and 2002. 384 women with primary invasive
breast cancer were compared with 566 screened women who were referred to the Unit and had
not developed breast neoplasm by the time the data were analysed. Risk factor data were obtained
from each subject by personal interviews using a structured questionnaire. The detection and
scoring of the HER-2/neu  protein, estrogen and progesterone receptor expression were
performed using immunochemistry. Odds ratios and 95% confidence intervals were determined by
chi-square test and logistic regression analysis. Case-case odds ratios were calculated in order to
measure the risk heterogeneity between HER-2/neu+ and HER-2/neu-tumours. Separate analyses
were performed for premenopausal and postmenopausal women and according to estrogen
receptor status.
Results: In multivariate analysis without HER-2/neu stratification, an increased breast cancer risk
was associated with only four of the factors examined: use of oral contraceptives (OR = 4.40,
95%C.I: 1.46–13.28), use of HRT (OR = 7.34, 95%C.I: 2.03–26.53), an age at first full pregnancy
more than 23 years (OR = 1.91, 95%C.I: 1.29–2.83) and body mass index more than 29 kg/m2 (OR
= 3.13, 95%C.I: 2.02–4.84). Additionally, a history of abortion or miscarriage (OR = 0.56, 95%C.I:
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0.38–0.82) was correlated with a decreased risk of breast cancer. In the case to case comparison
only BMI >29 kg/m2 revealed a relative connection that was stronger with positive than with
negative HER-2/neu tumours (ratio of OR's = 2.23, 95%C.I: 1.20–4.15, p = 0.011). This may indicate
evidence of heterogeneity of a rather significant degree for this factor. In the ER negative group an
age at first full pregnancy >23 years and a BMI >29 kg/m2 were associated with an increased risk in
both HER-2/neu groups, but the association was significantly stronger for the latter factor in the
positive HER-2/neu tumours (ratio of OR's = 2.46, 95%CI: 0.97–6.21).
Conclusions: Our study did not confirm that the established or putative hormonal breast cancer
risk factors differ regarding their relations with HER-2/neu+ versus HER-2/neu-breast tumours,
with the exception of increased BMI. Further innovative studies with larger sample sizes are needed
to examine how the status of these potentially modifiable breast cancer risk factors interacts with
biological markers such as HER-2/neu oncoprotein.
Background
The HER-2/neu oncogene, also known as c-erb-B2, c-neu
or ERBB2, is located in chromosome 17q11.2-12, encod-
ing an EGFR-family like glycoprotein [1]. Its amplifica-
tion, which is strongly correlated with protein
overexpression, occurs in about 15–43% of breast
tumours [1-10].
The observation that morphologically similar neoplas-
matic lesions of the breast can exhibit different biology
has necessitated the identification of biological parame-
ters that might improve risk assessment; the evaluation of
HER-2/neu expression is a typical example [11]. Indeed,
several studies have demonstrated that HER-2/neu ampli-
fication represents a prognostic and predictive marker; its
expression is associated with early disease recurrence, rel-
ative resistance to chemo- and/or hormonotherapy and
short survival [2,10]. In addition it has been shown that
genetic alterations of the HER-2/neu oncogene represent
early events involved in breast carcinogenesis and tumour
initiation, while their presence is observed in all stages of
malignant development from in situ carcinomas to meta-
static lesions [12]. As a result, some researchers have
maintained that HER-2/neu amplification and/or protein
overexpression may also represent not only an important
marker of prognosis but also a key indicator of the aetio-
logical heterogeneity of breast carcinogenesis. [3,7-9].
On the other hand, the contribution of even well estab-
lished breast cancer risk factors to the aetiology of carcino-
genesis in the breast remains obscure, ill-defined and
tenuous, mostly because of the existence of different path-
ways for the initiation and the evolution of a breast
tumour [13]. In order to explain this incompatibility, sev-
eral researchers have claimed that classification of
tumours on the basis of HER-2/neu  overexpression or
amplification may define a subset of breast cancer in
which the net effect of a risk factor could be rather more
obvious and its impact on breast cancer development
more clear [3,7,8].
Thus, a close correlation of a risk factor with HER-2/neu
overexpression could indicate either that a HER-2/neu
alteration is the way that this risk factor evolves into the
carcinogenesis or that there is a parallel interaction
between them that leads to breast tumour initiation and
development. Since the data in the literature supporting
the above hypothesis are few and conflicting, we decided
to investigate, in a group of patients from a geographical
area with a low incidence of breast cancer, whether HER-
2/neu positive tumours are correlated with established or
suspected risk factors for breast cancer and thus to identify
distinct subgroups of high risk women.
Methods
This study analysed data derived from the database of the
Breast Unit of the Department of Surgical Oncology at the
University General Hospital of Heraklion on the island of
Crete, Greece. The study considered all women who were
consecutively diagnosed with primary, invasive breast
cancer in our unit from 1996 to 2002. Subjects of other
races, ethnicity, with residence outside Crete or diagnosed
with DCIS or LCIS were excluded. Finally, 384 women, all
originating from the island of Crete, were eligible for
analysis.
An age-stratified random sample of 566 women was used
as a control group, derived from the Breast Unit's database
of screened patients who had not developed breast cancer
after a median follow up period of 40 months (range 12–
92 months). Personal interviews were conducted with
each woman during her first visit (both patients and con-
trols) by a consultant or a senior resident. The interview
followed a structured questionnaire, which did not
change during the study period. Anthropometric meas-
ures were also made during the first visit.
Women were classified as postmenopausal if their men-
strual cycles had ended naturally at least 12 months
before the interview or from surgery or radiation therapy
at any age. Those who reported not having menstrualBMC Women's Health 2005, 5:1 http://www.biomedcentral.com/1472-6874/5/1
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cycles for the last 10 months were considered as perimen-
opausal and were combined with premenopausal women
for the purpose of our analysis.
The following variables were analysed for all patients and
controls: residence (rural/urban), age at interview (≤ 50
and >50 years), age at menarche (≤ 12 and >12 years old),
age at first full birth (<23 vs. ≥ 23 years old), parity (nul-
liparous, 1 or 2, and >3), lactation (yes/no), use of medi-
cations to suppress lactation (yes/no), abortions and
miscarriages (yes/no), age at menopause for postmeno-
pausal women (≤ 50 and >50 years old), use of HRT for
more than 2 months (yes/no), use of oral contraceptives
for more than 2 months (yes/no), family history of breast
cancer in a first degree relative (yes/no), history of benign
breast disease (yes/no), obesity on the day of the interview
(BMI ≤ 29 kg/m2 vs. BMI>29 kg/m2, median value for the
study population) and radiation history of the chest (yes/
no).
Immunohistochemical study
For this study, tumour blocks were successfully retrieved
in 378 (98.4%) and in 377 (98.17%) of the 384 inter-
viewed cases for the immunohistochemical detection of
HER-2/neu  protein and hormone-receptor expression,
respectively.
Immunohistochemical detection and scoring of the HER-2/
neu protein expression
Immunohistochemistry with the monoclonal antibody
CB11 (NCLCB11, Novocastra Laboratories, UK 12 8EW),
at a dilution of 1/50 with incubation period of 60 min,
was performed using the OPTIMAX automated system
with the Super Sensitive Link-Label Detection System RTU
Multilink AP/Fast Red, QA200OXE (purchased from Bio-
genex Laboratories, San Ramon CA 94583 USA), follow-
ing antigen retrieval by microwave pre-treatment at 500
Watts for 3 × 5 min in citrate buffer (0.01 M, pH 6). Sec-
tions from breast cancer of known positivity were used as
positive controls. Negative controls were processed by
omitting the primary antibody and substituting non-
immune serum. Scoring was based on the criteria recom-
mended by DAKO A/S for the HercepTest [14]. Only
membrane staining pattern and intensity were scored
using the 0–3+ scale: scores of 0–1+ were considered neg-
ative, score 2+ was considered weak positive-need for
FISH, and score 3+ was considered (strongly) positive.
Immunohistochemical detection and scoring of estrogen 
and progesterone receptors
Three (3) µm-thick sections taken on negatively-charged
(SuperFrostPlus) slides were dewaxed in xylene, and rehy-
drated through graded alcohols. Following antigen
retrieval by microwave pre-treatment at 500 W for 3 × 5
min in citrate buffer (0.01 M, pH 6), estrogen receptor
(ERa) and progesterone receptor (PR) expression was
detected by immunohistochemistry using the same auto-
mated system and detection kit as above, and primary
monoclonal antibodies to ERa (DAKO M7047) and PR
(Biogenex code # MU 328-UC) at dilutions of 1/50 and 1/
20, respectively, with incubation time 60', at room tem-
perature. Positive and negative controls were processed as
above. Positive nuclei counting was performed at a final
magnification of 400× (Teaching double-headed NICON,
ECLIPSE E400 microscope, equipped with CFI 10X/22
oculars). After scanning at a final magnification of 100×
for locating the areas with highest density of ER+ or PR+
carcinoma cell nuclei (hot spots), a 40X/¥/0.17 WD 0.65
objective lens was used for cell counting. All carcinoma
cells in three hot spots per immunostained slide were
evaluated by two pathologists working simultaneously,
though independently, and the mean of the two inde-
pendent counts was considered the final counting value
for each field and hot spot. The ratio of the ER+ or PR+ car-
cinoma cell nuclei was recorded separately for each of the
hot spots. The final immunoreactivity index (score) was
calculated as the mean percentage of ER+ or PR+ carci-
noma cell nuclei in the three hot spots. Specimens were
interpreted as positive for ER or PR if at least 10% of the
cells demonstrated nuclear staining of any intensity of
reactivity, from 1+ to 3+. Staining intensity was graded as
negative (0), weak (1+), intermediate (2+) or strong (3+),
and reported separately. A mean value of intensity was
assigned for specimens in which the staining intensity var-
ied from field to field, and/or from hot spot to hot spot.
Statistical analysis
Odds ratios (OR) and 95% CI (confidence intervals), as
approximators of relative risk, were calculated to measure
the association of the groups of breast cancer and the risk
factors, using the chi-square (χ2) test. A p value <0.05 was
defined as significant. The potential association between
breast cancers stratified by HER-2/neu  status and well
known predisposing factors was further investigated by
using a stepwise logistic regression analysis (backward
LR), testing the independent effect of breast cancer risk
factors (independent variables) on breast cancer (depend-
ent variable) for all women and also separately for pre-
menopausal and postmenopausal females. In addition,
we undertook further stratification with estrogen receptor
status by using the same multivariate logistic regression
model. These patient-controls odds ratios helped us to
detect the pattern of heterogeneity and to explore plausi-
ble aetiological correlations between patient subgroups.
Additionally, case-case odds ratios were calculated in
order to measure the risk heterogeneity between HER-2/
neu+ and HER-2/neu-tumours. It seems that the departure
of the OR from unity can reveal the degree of heterogene-
ity between these subgroups [15].BMC Women's Health 2005, 5:1 http://www.biomedcentral.com/1472-6874/5/1
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Table 1: Characteristics of the participants
Factors Cases N = 384 n(%) Controls N = 566 n(%) OR1 (95% CI) OR2 (95% CI)
Age at interview
≤ 50 years 138(36) 178(31) 1.00
>50 years 246(64) 388(69) 0.82(0.62–1.08) NS
Area of residence
rural 189(49) 292(52) 1.00
urban 195(51) 274(48) 0.91(0.70–1.18) NS
Menopausal status
Pre/perimenopausal 134(35) 170(30) 1.00
Postmenopausal 250(65) 396(70) 0.80(0.60–1.06) NS
Age at menopause3
≤ 50 years 144(59) 252(64) 1.00
>50 years 102(41) 140(36) 1.28(0.92–1.77) NS
Age of menarche
≤ 12 years 155(40) 150(27) 1.86(1.41–2.45)
>12 years 229(60) 412(73) 1.00 NS
Use of oral contraceptives
no 341(89) 548(97) 1.00 1.00
yes 43(11) 18(3) 3.84(2.18–6.77) 4.40(1.46–13.28)
Use of HRT3
no 231(92) 393(99) 1.00 1.00
yes 19(8) 3(1) 10.78(3.15–36.81) 7.34(2.03–26.53)
First degree family history
no 341(89) 522(92) 1.00
yes 43(11) 44(8) 1.5(0.96–2.33) NS
Age at first full pregnancy
<23 years 106(35) 239(50) 1.00 1.00
≥ 23 years 197(65) 242(50) 1.84(1.37–2.47) 1.91(1.29–2.83)
Parity
nulliparous 79(20) 78(14) 1.00
1–2 175(46) 255(45) 0.68(0.47–0.98) NS
3 plus 130(34) 233(41) 0.55(0.38–0.80) NS
Abortion or miscarriage
no 183(57) 247(50) 1.00 1.00
yes 138(43) 248(50) 0.75(0.57–0.99) 0.56(0.38–0.82)
Lactation
no 67(22) 84(17) 1.00
yes 238(78) 404(82) 0.74(0.52–1.06) NS
Medication to suppress lactation
no 273(90) 438(90) 1.00
yes 31(10) 50(10) 0.99(0.62–1.60) NS
Radiation to the chest
no 372(97) 550(97) 1.00
yes 12(3) 16(3) 1.11(0.52–2.37) NS
Body mass index
≤ 29 kg/m2 282(74) 498(88) 1.00 1.00
>29 kg/m2 97(26) 68(12) 2.52(1.79–3.55) 3.13 (2.03–4.84)
Benign breast disease
no 315(82) 472(83) 1.00
yes 69(18) 94(17) 1.10(0.78–1.55) NS
1Adjusted for age. -2Adjusted for age, residence, menopausal status, menopausal age, menarche age, use of OC, use of HRT, first degree family 
history, age at first full pregnancy, parity, abortion, lactation, medication to suppress lactation, radiation to the chest, body mass index and benign 
breast disease. -3Postmenopausal women only.
NS: non significant multivariate OR. Bold types: statistically significant values.BMC Women's Health 2005, 5:1 http://www.biomedcentral.com/1472-6874/5/1
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Results
Risk factor distributions in breast cancer patients and
matched controls are presented in table 1. The mean age
at interview was 56.30 years. When all patients were com-
pared with matched controls, and after adjustment for
confounding factors, an increased breast cancer risk was
associated with only four of the factors examined: use of
oral contraceptives (OR = 4.40, 95%C.I: 1.46–13.28), use
of HRT (OR = 7.34, 95%C.I: 2.03–26.53), an age at first
full pregnancy more than 23 years (OR = 1.91, 95%C.I:
1.29–2.83) and body mass index more than 29 kg/m2 (OR
= 3.13, 95%C.I: 2.02–4.84). Additionally, a history of
abortion or miscarriage (OR = 0.56, 95%C.I: 0.38–0.82)
was correlated with a decreased risk of breast cancer. How-
ever, the number of oral contraceptive and HRT users was
too small for reliable estimates of risk.
Tumour characteristics of breast cancer patients are shown
in table 2. Thirty eight percent (145/378) of the tumours
showed HER-2/neu  protein overexpression. HER-2/neu
positive tumours were not related with menopausal state,
age at interview, tumour size, grade and stage, nodal and
estrogen receptor status, but there was a modest positive
association between HER-2/neu and progesterone nega-
tive tumours.
Menopausal status and estrogen receptor stratification
Subgroups of women stratified by menopausal status were
further analysed by a multivariate stepwise logistic regres-
sion model adjusted for the remaining variables (table 3).
In the premenopausal group of women, an increased risk
for HER-2/neu-tumours was observed for those women
who reported an age at first full pregnancy ≥ 23 years (OR
= 3.56, 95%C.I: 1.70–7.46), a BMI>29 kg/m2(OR = 6.89,
Table 2: Characteristics of the tumours of breast cancer patients1.
Tumour characteristics HER-2/neu + n = 145 (%) HER-2/neu- n = 233 (%) p value
Age at interview 0.533
≤ 50 years 55 (40) 81 (60)
>50 years 90 (37) 152 (63)
Staging 0.106
I 30 (45) 36 (55)
II 76 (35) 143 (65)
III 20 (34) 39 (66)
IV 2 (50) 2 (50)
Unknown 17 (57) 13 (43)
Tumour size 0.161
T1 55 (44) 71 (56)
T2 65 (35) 121 (65)
>T3 10 (29) 25 (71)
Unknown 15 (48) 16 (52)
Menopausal status 0.762
Pre/perimenopausal 52 (40) 80 (60)
Postmenopausal 93 (38) 153 (62)
Grading 0.577
I 7 (33) 14 (67)
II 64 (36) 113 (64)
III 60 (43) 80 (57)
Unknown 14 (35) 26 (65)
Node Status 0.119
Negative 55 (33) 112 (67)
Positive 89 (43) 118 (57)
Unknown 1 (25) 3 (75)
Estrogen receptor status 0.108
Er+ 60 (33) 120 (67)
Er - 85 (43) 112 (57)
Unknown 1
Progesterone receptor status 0.038
Pr+ 49 (49) 52 (51)
Pr- 96 (35) 180 (65)
Unknown 1
1Data for HER-2/neu status were missing for 6 of the 384 interviewed cases.BMC Women's Health 2005, 5:1 http://www.biomedcentral.com/1472-6874/5/1
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95%C.I: 2.23–21.25), first degree family history (OR =
3.30, 95%C.I:1.10–9.96) or use of oral contraceptives (OR
= 11.19, 95%C.I 3.70–33.84), while an age at menarche
less than 12 years was the only factor which slightly
increased the risk in premenopausal HER-2/neu+ patients
(OR = 2.09, 95%C.I 0.99–4.42). Abortion played a less
protective role (p = 0.068) for HER-2/neu-breast cancer in
premenopausal than in postmenopausal women (p =
0.038). However, the intercase comparison in the premen-
opausal subgroup showed an evidence of heterogeneity
only for the HER-2/neu+ women who had ever had an
abortion (ratio of the OR's = 3.12, 95%C.I:1.18–8.24),
while use of oral contraceptives (OR = 0.16, 95%C.I:
0.04–0.60, p = 0.007) and a positive first degree family
history (OR = 0.09, 95%C.I: 0.01–0.85, p = 0.035) showed
a stronger association for HER-2/neu negative tumours.
The results of logistic regression were identical for all
women and the postmenopausal groups of patients due to
the large sample size. Patients with an age of menarche ≤
12 years (OR = 1.72, 95%C.I: 1.07–2.75), first degree fam-
ily history (OR = 2.23, 95%C.I:1.08–4.63), use of HRT
(OR = 10.70, 95%C.I: 2.71–42.31) or OC (OR = 6.47,
95%C.I:1.89–22.16) were at increased risk of developing
HER-2/neu-breast cancer only, although the significance
of the latter two factors was of little value due to the lim-
ited sample size. On the other hand, an age at first full
pregnancy ≥ 23 years and a BMI greater than 29 kg/m2
increased breast cancer risk independently of HER-2/neu
status, while a history of abortion decreased risk in the
same way. In the case to case comparison only BMI >29 kg/
m2 revealed a relative stronger connection with positive
than with negative HER-2/neu tumours (ratio of OR's =
2.23, 95%C.I: 1.20–4.15, p = 0.011) and this may indicate
an evidence of heterogeneity of a rather significant degree
for this factor. The stronger association between an age at
menarche ≤ 12 years, use of HRT and negative as opposed
to positive HER-2/neu status did not reach statistical sig-
nificance (p = 0.067 and p = 0.062, respectively).
A different stratification pattern of our study's population
is presented in table 4. This multivariate model, further
stratified by estrogen receptor status, confirmed the
observed tight connections between HER-2/neu positivity
and obesity already shown in the analysis so far. In more
detail, although BMI >29 kg/m2 elevated risk for both ER
Table 3: Multivariate analysis of risk factors and HER-2/neu overexpression according to menopausal status




Ratio of the OR's Cases+/cases- 
OR (95% CI)
PREMENOPAUSAL
Age at first full pregnancy(≥ 23 years) NS 3.56(1.70–7.46) NS
Body mass index(>29 kg/m2) NS 6.89(2.23–21.25) NS
Abortion or miscarriage(ever) NS 0.49(0.23–1.05) 3.12 (1.18–8.24)
First degree family history(positive) NS 3.30(1.10–9.96) 0.09 (0.01–0.85)
Use of oral contraceptives (ever) NS 11.19(3.7–33.84) 0.16 (0.04–0.60)
Age of menarche (≤ 12 years) 2.09 (0.99–4.42) NS NS
POSTMENOPAUSAL
Age at first full pregnancy(≥ 23 years) 2.19(1.23–3.91) 1.66(1.03–2.66) NS
Body mass index(>29 kg/m2) 4.83(2.75–8.49) 2.67(1.56–4.55) 2.23 (1.20–4.15)
Abortion or miscarriage(ever) 0.50(0.28–0.88) 0.62(0.39–0.97) NS
First degree family history(positive) NS 2.23(1.08–4.63) NS
Use of estrogens (ever) NS 10.70(2.71–42.31) 0.21 (0.04–1.08)
Use of oral contraceptives (ever) NS 6.47(1.89–22.16) NS
Age of menarche (≤ 12 years) NS 1.72(1.07–2.75) 0.54 (0.28–1.04)
ALL WOMEN
Age at first full pregnancy(≥ 23 years) 2.19(1.23–3.91) 1.66 (1.03–2.66) NS
Body mass index(>29 kg/m2) 4.83(2.75–8.49) 2.67(1.56–4.55) 2.23(1.20–4.15)
Abortion or miscarriage(ever) 0.50(0.28–0.88) 0.62(0.39–0.97) NS
First degree family history(positive) NS 2.23(1.08–4.63) NS
Use of estrogens (ever) NS 10.70(2.71–42.31) 0.21 (0.04–1.08)
Use of oral contraceptives (ever) NS 6.47(1.88–22.16) NS
Age of menarche (≤ 12 years) NS 1.72(1.07–2.75) 0.54 (0.28–1.04)
Adjusted for age, residence, menopausal status, menopausal age, menarche age, use of OC, use of HRT, first degree family history, age at first full 
pregnancy, parity, abortion, lactation, medication to suppress lactation, radiation to the chest, body mass index and benign breast disease.
NS: non significant.BMC Women's Health 2005, 5:1 http://www.biomedcentral.com/1472-6874/5/1
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negative and positive tumours independently of HER-2/
neu status, the association was significantly stronger for
positive HER-2/neu  tumours in the ER negative group
(ratio of OR's = 2.46, 95%CI: 0.97–6.21). Additionally, in
the same group an age at first full pregnancy >23 years
revealed an increase of risk in both HER-2/neu groups,
while first degree family history (OR = 2.72, 95%C.I:
1.05–7.07, p = 0.040), age at menopause >50 years (OR =
2.05, 95%C.I: 1.10–3.79, p = 0.023) and birth of 1–2 chil-
dren (OR = 2.38, 95%C.I: 1.21–4.67, p = 0.012) elevated
risk for HER-2/neu  negative tumours only. In the ER+
group of women the direct comparison between cases
revealed no associations with any factor at all, while abor-
tion showed a protective pattern against breast cancer
which expressed estrogen receptors independently of
HER-2/neu status.
Discussion
This epidemiological study, conducted in a low incidence
Mediterranean population, [16] found that obesity was
related with postmenopausal breast tumours that overex-
press HER-2/neu oncoprotein. In fact, increased BMI ele-
vated risk in both groups, but the comparison between
HER-2/neu+ and HER-2/neu- tumours revealed a much
stronger association with HER-2/neu+ breast cancers.
Very few studies have examined the possibility whether
HER-2/neu status can help discriminate aetiologically dis-
tinct subgroups of breast cancer cases, and none of them
has identified the effect of increased BMI with HER-2/neu
positive tumours [3,5,7-9].
More specifically, in contrast with other investigators who
have shown an elevated risk for HER-2/neu+ tumours with
an early age at first full pregnancy, we found a strong
elevated risk with a late age regardless of HER-2/neu pro-
tein expression [3]. Previous findings suggested an inverse
relationship between abortion and HER-2/neu+ breast
cancers, while we also found this inverse association but
independently of HER-2/neu  status [7]. Interestingly
enough, abortion increased risk for HER-2/neu+ tumours
only in the premenopausal group of women. Early contra-
ceptive use has been positively associated with HER-2/
neu+ breast cancer in two studies [7,8], but our findings
were different, revealing a positive association with HER-
2/neu negative tumours. However, because the number of
oral contraceptive (and HRT) users in this study was
small, this subgroup analysis was hindered by decreased
power to detect associations of any magnitude. The
slightly protective effect of parity found in the age-
adjusted analysis was diminished after logistic regression
and did not reveal any association with HER-2/neu status,
in contrast with previous findings [7]. Breastfeeding was
associated with increased risks for breast cancer in women
with HER-2/neu  positive tumours in one study while
other investigators reported opposite results [3,9].
Although our study population showed a remarkable lac-
tation incidence (almost 80% of the participants) we
found no associations at all.
Our findings have similarities and differences with respect
to previous reports that examined the associations of
breast risk factors with HER-2/neu status. This inconsist-
ency may reflect differences in study design, populations,
and laboratory methodology. In this study we used
immunochemistry (CB11 monoclonal antibody) to
assess the HER-2/neu  protein overexpression, which is
highly correlated with gene amplification according to
previous reports [2,4]. Also, the percentage of women
with breast cancer and HER-2/neu protein overexpression
Table 4: Multivariate analysis of risk factors and HER-2/neu overexpression according to ER1 status.




Ratio of the OR's Cases+/cases- 
OR (95% CI)
ER + cases
Body mass index(>29 kg/m2) 5.59 (2.58–12.13) 2.84 (1.52–5.32) NS
Age at 1st pregnancy (≥ 23 years) 2.09 (0.97–4.53) NS NS
First degree family history (positive) NS 2.18 (0.92–5.14) NS
Abortion or miscarriage (ever) 0.44 (0.20–0.95) 0.56 (0.32–0.99) NS
ER – cases
Body mass index(>29 kg/m2) 5.33 (2.59–10.94) 2.41 (1.15–5.04) 2.46 (0.97–6.21)
Age at 1st pregnancy (≥ 23 years) 2.37 (1.08–5.18) 1.78 (0.93–3.42) NS
First degree family history (positive) NS 2.72 (1.05–7.07) NS
Age of menopause (>50 years) NS 2.05 (1.10–3.79) NS
Parity (1–2 children) NS 2.38 (1.21–4.67) NS
Adjusted for age, residence, menopausal status, menopausal age, menarche age, use of OC, use of HRT, first degree family history, age at first full 
pregnancy, parity, abortion, lactation, medication to suppress lactation, radiation to the chest, body mass index and benign breast disease.
1ER: estrogen receptor. NS: non significant.BMC Women's Health 2005, 5:1 http://www.biomedcentral.com/1472-6874/5/1
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found here was within the limits reported elsewhere [3,5-
9].
This lack of relationship between HER-2/neu protein over-
expression and most of the hormone-related breast cancer
risk factors does not completely agree with several
hypotheses which have maintained that combined estro-
gen and HER-2/neu activation is closely involved in the
same pathway in breast cancer carcinogenesis [17,18].
The only hormone-related factor that was found to be
related with HER-2/neu positive tumours in our study was
high body mass index, which is an established risk factor
that has an estrogen-mediated oncogenic effect on the
mammary gland. More specifically, obesity is associated
with higher breast cancer risk among postmenopausal
women through greater lifetime exposure to higher levels
of estrogens produced in adipose tissue and lower SHBG
production [19,20]. Higher levels of circulating estrogens
enhance the rate of cell division, and this hormone-
induced cellular proliferation can result in somatic muta-
tions and finally lead to a malignant change. These altera-
tions involve many genes, including those concerned with
hormone metabolism and transport, DNA repair, as well
as tumour suppressor genes and oncogenes such as the
HER-2/neu gene [18,21]. According to some investigators,
circulating estrogens can stimulate breast cancer cell pro-
liferation, not only through hormone receptors, but also
through the HER-2/neu receptor, and so promote carcino-
genesis through common means [4,17,18].
Numerous epidemiological and experimental studies
have shown the strong relationship between HER-2/neu-
positivity and lack of hormone receptor expression in
breast tumours [2,10,18,22]. In our study, HER-2/neu
positive tumours were weakly related with the absence of
estrogen receptors, although this was not statistically sig-
nificant (see table 2). Because different ER status can result
in different correlations between risk factors and HER-2/
neu+ breast cancer, it is always important to examine these
interactions under ER stratification [8]. Since antiestro-
gens can lower HER-2/neu levels in ER negative tumours,
it is possible that an excess of estrogens can stimulate
HER-2/neu  in these tumours [8,18]. This mechanism
could explain the stronger association between obesity (a
situation with an overload of estrogens as mentioned
above) and HER-2/neu-positivity among ER negative
patients that was found in the present study (see table 5).
The interview was conducted during the subjects' first visit
to the unit and before clinical examination or any other
intervention took place. This constitutes an advantage,
because there was no chance that the subjects (both cases
and controls) would be influenced by the diagnosis and
might therefore falsely inflate the relative risk. Thus, the
likelihood of recall bias is not high, improving the com-
parability of several covariates in both groups, and the
selection bias is lessened since all subjects had taken the
same route through the Breast Unit's standard routine
procedures.
Since each case group was compared with the same con-
trol group, any selection bias would be expected to have a
similar effect on the estimates in the tumour subgroups.
Thus, it is extremely unlikely that recall bias issues would
apply only to those cases in a specific HER-2/neu status
subgroup. Some caution regarding our findings is related
to the size of the study group. In the analyses stratified by
HER-2/neu  and menopausal or ER status numbers are
quite small and for some risk estimates the confidence
intervals are wide and the estimates of risk unstable.
Conclusions
In conclusion, our study did not confirm that the estab-
lished or putative hormonal breast cancer risk factors dif-
fer regarding their relations with HER-2/neu+ versus HER-
2/neu-breast tumours, with the exception of increased
BMI. Further innovative studies with larger sample sizes
are needed to examine how the status of these potentially
modifiable breast cancer risk factors interacts with biolog-
ical markers such as HER-2/neu oncoprotein. Their find-
ings will provide us with greater insight into breast cancer
aetiology and will help us identify any association that
would help discriminate subgroups of women at higher
risk.
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